Abstract：
OBJECTIVE: To evaluate the prognostic value of the pretreatment maximum standardized uptake value (SUVmax) for locoregional control (LRC) of early glottic cancer treated with primary radiotherapy.
METHODS: We retrospectively reviewed the medical records of 101 patients with T1-T2N0 glottic cancer treated with helical tomotherapy between 2013 and 2016. The clinical T-stages were T1 in 87 (86.1%) and T2 in 14 (13.9%) patients. The median total dose was 63 Gy (63-67.5 Gy) in 2.25 Gy per fraction. The survival outcomes were plotted using Kaplan-Meier curves. Receiver operating characteristic curves were used to assess the optimal SUVmax cut-off value for predicting locoregional recurrence.
RESULTS: The median follow-up period was 58 months (range, 11 to 90 months). The 5-year overall survival (OS) and locoregional recurrence-free survival rates were 96.8% and 85.4%, respectively. The median pretreatment SUVmax of the primary tumor for all 101 patients was 2.3 (range, 1.1 to 9.1). The best cut-off value for SUVmax for predicting LRC was 3.3, with a sensitivity of 78.6% and specificity of 73.6%. Univariate analysis showed that T-stage, overall treatment time (≥43 days), and high SUVmax (≥3.3) were significant predictors of LRC. Multivariate analysis showed that LRC was independently affected by a high SUVmax (≥3.3) (hazard ratio = 5.505, p = 0.020).
CONCLUSIONS: High pretreatment SUVmax (≥3.3) is a negative prognostic factor for LRC in early glottic cancer patients treated with primary radiotherapy.
METHODS: We retrospectively reviewed the medical records of 101 patients with T1-T2N0 glottic cancer treated with helical tomotherapy between 2013 and 2016. The clinical T-stages were T1 in 87 (86.1%) and T2 in 14 (13.9%) patients. The median total dose was 63 Gy (63-67.5 Gy) in 2.25 Gy per fraction. The survival outcomes were plotted using Kaplan-Meier curves. Receiver operating characteristic curves were used to assess the optimal SUVmax cut-off value for predicting locoregional recurrence.
RESULTS: The median follow-up period was 58 months (range, 11 to 90 months). The 5-year overall survival (OS) and locoregional recurrence-free survival rates were 96.8% and 85.4%, respectively. The median pretreatment SUVmax of the primary tumor for all 101 patients was 2.3 (range, 1.1 to 9.1). The best cut-off value for SUVmax for predicting LRC was 3.3, with a sensitivity of 78.6% and specificity of 73.6%. Univariate analysis showed that T-stage, overall treatment time (≥43 days), and high SUVmax (≥3.3) were significant predictors of LRC. Multivariate analysis showed that LRC was independently affected by a high SUVmax (≥3.3) (hazard ratio = 5.505, p = 0.020).
CONCLUSIONS: High pretreatment SUVmax (≥3.3) is a negative prognostic factor for LRC in early glottic cancer patients treated with primary radiotherapy.
摘要：
目的：评估预处理最大标准化摄取值（SUVmax）对早期声门型喉癌的局部区域控制（LRC）的预后价值。
方法：我们回顾性回顾了2013年至2016年间接受螺旋断层治疗的101例T1-T2N0声门癌患者的病历。87例患者的临床T分期为T1（86.1％），14例（13.9％）为T2。平均总剂量为63Gy(63-67.5Gy),每分2.25Gy。使用Kaplan-Meier曲线绘制生存结果。接收器工作特征曲线用于评估用于预测局部复发的最佳SUVmax截止值。
结果：中位随访期为58个月（范围，11至90个月）。5年总生存率（OS）和局部无复发生存率分别为96.8%和85.4%，分别。所有101例患者的原发性肿瘤的中位治疗前SUVmax为2.3（范围，1.1to9.1).SUVmax预测LRC的最佳临界值为3.3，灵敏度为78.6%，特异性为73.6%。单因素分析表明，T期，总治疗时间（≥43天），高SUVmax(≥3.3)是LRC的显著预测因子。多变量分析显示，LRC受到高SUVmax（≥3.3）的独立影响（风险比=5.505，p=0.020）。
结论：高治疗前SUVmax(≥3.3)是早期声门型喉癌患者接受初级放疗的不良预后因素。
方法：我们回顾性回顾了2013年至2016年间接受螺旋断层治疗的101例T1-T2N0声门癌患者的病历。87例患者的临床T分期为T1（86.1％），14例（13.9％）为T2。平均总剂量为63Gy(63-67.5Gy),每分2.25Gy。使用Kaplan-Meier曲线绘制生存结果。接收器工作特征曲线用于评估用于预测局部复发的最佳SUVmax截止值。
结果：中位随访期为58个月（范围，11至90个月）。5年总生存率（OS）和局部无复发生存率分别为96.8%和85.4%，分别。所有101例患者的原发性肿瘤的中位治疗前SUVmax为2.3（范围，1.1to9.1).SUVmax预测LRC的最佳临界值为3.3，灵敏度为78.6%，特异性为73.6%。单因素分析表明，T期，总治疗时间（≥43天），高SUVmax(≥3.3)是LRC的显著预测因子。多变量分析显示，LRC受到高SUVmax（≥3.3）的独立影响（风险比=5.505，p=0.020）。
结论：高治疗前SUVmax(≥3.3)是早期声门型喉癌患者接受初级放疗的不良预后因素。
